AQST (STOCKS)
Aquestive Therapeutics, Inc. Common Stock
$4.720000
+0.290000 (+6.55%)
Prev close: $4.430000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Daniel Barber
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $590.87M
- Employees
- 142
- P/E (TTM)
- -7.81
- P/B (TTM)
- -17.19
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
4
Strong Buy
10
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.07 | $-0.14 | +0.0699 | +49.96% |
|
Dec 2025 (Q4)
|
$-0.15 | $-0.14 | -0.0148 | -10.95% |
|
Sep 2025 (Q3)
|
$-0.14 | $-0.14 | -0.0048 | -3.55% |
|
Jun 2025 (Q2)
|
$-0.14 | $-0.17 | +0.0317 | +18.46% |
Financial Statements
| Revenues | $50.27M |
| Benefits Costs and Expenses | $119.18M |
| Cost Of Revenue | $18.37M |
| Costs And Expenses | $106.16M |
| Gross Profit | $31.90M |
| Operating Expenses | $87.79M |
| Selling, General, and Administrative Expenses | $71.75M |
| Depreciation and Amortization | $522.00K |
| Research and Development | $16.04M |
| Operating Income/Loss | -$55.89M |
| Income/Loss From Continuing Operations After Tax | -$68.91M |
| Income/Loss From Continuing Operations Before Tax | -$68.91M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$68.91M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$68.91M |
| Net Income/Loss Available To Common Stockholders, Basic | -$68.91M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.62 |
| Diluted Earnings Per Share | -$0.62 |
| Basic Average Shares | 337,589,621 |
| Diluted Average Shares | 337,589,621 |
| Assets | $141.13M |
| Current Assets | $130.18M |
| Accounts Receivable | $6.87M |
| Inventory | $8.07M |
| Other Current Assets | $115.25M |
| Noncurrent Assets | $10.94M |
| Fixed Assets | $3.84M |
| Other Non-current Assets | $7.10M |
| Liabilities | $175.18M |
| Current Liabilities | $31.75M |
| Accounts Payable | $11.89M |
| Wages | $2.07M |
| Other Current Liabilities | $17.80M |
| Noncurrent Liabilities | $143.43M |
| Long-term Debt | $45.00M |
| Other Non-current Liabilities | $98.43M |
| Equity | -$34.05M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$34.05M |
| Liabilities And Equity | $141.13M |
| Net Cash Flow From Operating Activities | -$43.84M |
| Net Cash Flow From Operating Activities, Continuing | -$43.84M |
| Net Cash Flow From Investing Activities | -$479.00K |
| Net Cash Flow From Investing Activities, Continuing | -$479.00K |
| Net Cash Flow From Financing Activities | $86.39M |
| Net Cash Flow From Financing Activities, Continuing | $86.39M |
| Net Cash Flow | $42.08M |
| Net Cash Flow, Continuing | $42.08M |
| Comprehensive Income/Loss | -$68.91M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$68.91M |
| Other Comprehensive Income/Loss | -$55.36M |